All In Biotech

Free tool

FAERS Monitor: Pylera

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050786 or its brand name (Pylera, Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,133

Serious

940

83% of reports

Hospitalization

419

Death reported

18

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea123
  • headache111
  • diarrhoea102
  • dizziness81
  • faeces discoloured81
  • asthenia76
  • vomiting75
  • off label use68
  • pruritus61
  • fatigue60
  • abdominal pain upper55
  • dyspnoea54
  • pyrexia49
  • abdominal pain48
  • paraesthesia47

Reports by year received

View as table
YearReports
200811
200918
20107
20112
20123
201335
201446
201573
201680
201783
2018106
201986
2020113
202194
202281
202353
202481
202595
202666

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,026 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
faeces discolouredSignal8169.656.45,397
paraesthesiaSignal475.54.2172
abdominal pain upperSignal555.03.8172
abdominal painSignal483.82.999
astheniaSignal763.83.0153
headacheSignal1113.32.8180
dizzinessSignal813.02.4110
vomitingSignal753.02.498
pruritusSignal612.92.378
diarrhoeaSignal1022.92.4132
nauseaSignal1232.92.4155
pyrexiaSignal492.62.049
dyspnoea541.81.418
off label use681.41.19
fatigue601.41.18

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.